Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 926 to 950 of 1150 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
618 increased reflex (GO:0060004) trigeminal nerve (UBERON:0001645) 1223: Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea
631 increased reflex (GO:0060004) sneezing (MESH:D012912) 1434: Irritation of nasal mucosa inducing sneeze reflex
1102 increased regulation of actin-dependent ATPase activity (GO:1904621) actin cytoskeleton (GO:0015629) 2078: Loss of drebrin
1030 increased regulation of androgen receptor signaling pathway (GO:0060765) androgen receptor (PR:000004191) 2274: Androgen receptor activation, increased
771 occurrence regulation of beta-catenin-TCF complex assembly (GO:1904863) beta-catenin-TCF complex (GO:1990907) 1755: beta-catenin activation
743 decreased regulation of binding (GO:0051098) None
747 decreased regulation of binding (GO:0051098) tyrosine-protein kinase JAK3 (PR:000009198) 1715: Inhibition of JAK3
1015 decreased regulation of body fluid levels (GO:0050878) blood plasma (UBERON:0001969) None
701 disrupted regulation of cell cycle (GO:0051726) cell cycle-related cyclin (PR:000029191) 1505: Increase, Cell cycle disruption
773 occurrence regulation of cellular response to drug (GO:2001038) 1651: Treatment-resistant gastric cancer
628 increased regulation of chemokine (C-X-C motif) ligand 1 production (GO:2000338) growth-regulated alpha protein (PR:000006063) 1235: Non-neuronal production of IL-8/CXCL1, Epithelial irritation
830 increased regulation of chronic inflammatory response (GO:0002676) 1868: Hyperinflammation
793 decreased regulation of cilium movement (GO:0003352) None
1127 decreased regulation of DNA binding (GO:0051101) androgen (CHEBI:50113) 2393: Androgen receptor nuclear transcriptional activity in genital-tubercle tissues, reduced
976 disrupted regulation of gene expression (GO:0010468) 2224: Dysregulation of transcriptional expression within PPAR signaling network
377 abnormal regulation of gene expression (GO:0010468) 1214: Altered gene expression specific to CAR activation, Hepatocytes
42 abnormal regulation of gene expression (GO:0010468) hippocampal formation (UBERON:0002421) 756: Hippocampal gene expression, Altered
99 decreased regulation of gene expression (GO:0010468) androgen receptor (PR:000004191) 286: Altered, Transcription of genes by the androgen receptor
706 decreased regulation of hormone levels (GO:0010817) thyroxine (CHEBI:30660) 280: Thyroxine (T4) in neuronal tissue, Decreased
758 increased regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122) 1172: Increased activation, Nuclear factor kappa B (NF-kB)
458 decreased regulation of intracellular pH (GO:0051453) 867: Decrease, Intracellular pH
294 decreased regulation of luteinizing hormone secretion (GO:0033684) Luteinizing hormone (CHEBI:81568) 531: Decreased, LH Surge
798 decreased regulation of mitochondrial membrane potential (GO:0051881) mitochondrion (GO:0005739) 1446: Decrease, Coupling of oxidative phosphorylation
813 increased regulation of peptidase activity (GO:0052547) angiotensin-converting enzyme (human) (PR:P12821) None
699 increased regulation of protein modification process (GO:0031399) histone (CHEBI:15358) 1503: Histone acetylation, increase